These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 21074058)

  • 21. Profile of ipilimumab and its role in the treatment of metastatic melanoma.
    Patel SP; Woodman SE
    Drug Des Devel Ther; 2011; 5():489-95. PubMed ID: 22267918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ipilimumab in the treatment of melanoma.
    Trinh VA; Hwu WJ
    Expert Opin Biol Ther; 2012 Jun; 12(6):773-82. PubMed ID: 22500861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
    Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
    JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy.
    Callahan MK; Wolchok JD; Allison JP
    Semin Oncol; 2010 Oct; 37(5):473-84. PubMed ID: 21074063
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ipilimumab. Immunostimulant; more assessment needed.
    Prescrire Int; 2012 Jun; 21(128):145-7. PubMed ID: 22822590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ipilimumab lesson in melanoma: achieving long-term survival.
    Delyon J; Maio M; Lebbé C
    Semin Oncol; 2015 Jun; 42(3):387-401. PubMed ID: 25965357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
    Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
    J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
    Small EJ; Tchekmedyian NS; Rini BI; Fong L; Lowy I; Allison JP
    Clin Cancer Res; 2007 Mar; 13(6):1810-5. PubMed ID: 17363537
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
    Yamazaki N; Kiyohara Y; Uhara H; Fukushima S; Uchi H; Shibagaki N; Tsutsumida A; Yoshikawa S; Okuyama R; Ito Y; Tokudome T
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):997-1004. PubMed ID: 26410424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
    Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
    [No Abstract]   [Full Text] [Related]  

  • 37. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
    Beck KE; Blansfield JA; Tran KQ; Feldman AL; Hughes MS; Royal RE; Kammula US; Topalian SL; Sherry RM; Kleiner D; Quezado M; Lowy I; Yellin M; Rosenberg SA; Yang JC
    J Clin Oncol; 2006 May; 24(15):2283-9. PubMed ID: 16710025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
    Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
    N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.
    Voskens CJ; Goldinger SM; Loquai C; Robert C; Kaehler KC; Berking C; Bergmann T; Bockmeyer CL; Eigentler T; Fluck M; Garbe C; Gutzmer R; Grabbe S; Hauschild A; Hein R; Hundorfean G; Justich A; Keller U; Klein C; Mateus C; Mohr P; Paetzold S; Satzger I; Schadendorf D; Schlaeppi M; Schuler G; Schuler-Thurner B; Trefzer U; Ulrich J; Vaubel J; von Moos R; Weder P; Wilhelm T; Göppner D; Dummer R; Heinzerling LM
    PLoS One; 2013; 8(1):e53745. PubMed ID: 23341990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
    Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
    J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.